147 related articles for article (PubMed ID: 34013974)
21. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.
Troeger A; Johnson AJ; Wood J; Blum WG; Andritsos LA; Byrd JC; Williams DA
Blood; 2012 May; 119(20):4708-18. PubMed ID: 22474251
[TBL] [Abstract][Full Text] [Related]
22. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.
Chanan-Khan AA; Chitta K; Ersing N; Paulus A; Masood A; Sher T; Swaika A; Wallace PK; Mashtare TL; Wilding G; Lee K; Czuczman MS; Borrello I; Bangia N
Br J Haematol; 2011 Nov; 155(4):457-67. PubMed ID: 22010965
[TBL] [Abstract][Full Text] [Related]
23. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
Maffei R; Fiorcari S; Martinelli S; Benatti S; Bulgarelli J; Rizzotto L; Debbia G; Santachiara R; Rigolin GM; Forconi F; Rossi D; Laurenti L; Palumbo GA; Vallisa D; Cuneo A; Gaidano G; Luppi M; Marasca R
Leuk Lymphoma; 2018 Feb; 59(2):423-433. PubMed ID: 28639485
[TBL] [Abstract][Full Text] [Related]
24. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
[TBL] [Abstract][Full Text] [Related]
25. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.
Andritsos LA; Johnson AJ; Lozanski G; Blum W; Kefauver C; Awan F; Smith LL; Lapalombella R; May SE; Raymond CA; Wang DS; Knight RD; Ruppert AS; Lehman A; Jarjoura D; Chen CS; Byrd JC
J Clin Oncol; 2008 May; 26(15):2519-25. PubMed ID: 18427150
[TBL] [Abstract][Full Text] [Related]
26. Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways?
Seke Etet PF; Vecchio L; Nwabo Kamdje AH
Cell Signal; 2012 Jul; 24(7):1433-43. PubMed ID: 22446006
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.
Strati P; Takahashi K; Peterson CB; Keating MJ; Thompson PA; Daver NG; Jain N; Burger JA; Estrov Z; O'Brien SM; Kantarjian HM; Wierda WG; Futreal PA; Ferrajoli A
Blood Adv; 2019 May; 3(9):1533-1539. PubMed ID: 31076409
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
29. Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target.
Hegde GV; Peterson KJ; Emanuel K; Mittal AK; Joshi AD; Dickinson JD; Kollessery GJ; Bociek RG; Bierman P; Vose JM; Weisenburger DD; Joshi SS
Mol Cancer Res; 2008 Dec; 6(12):1928-36. PubMed ID: 19074837
[TBL] [Abstract][Full Text] [Related]
30. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro.
Panayiotidis P; Jones D; Ganeshaguru K; Foroni L; Hoffbrand AV
Br J Haematol; 1996 Jan; 92(1):97-103. PubMed ID: 8562418
[TBL] [Abstract][Full Text] [Related]
31. Lenalidomide as first-line therapy for elderly CLL patients.
Gilbert JA
Lancet Oncol; 2013 Aug; 14(9):e345. PubMed ID: 24058966
[No Abstract] [Full Text] [Related]
32. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.
Aue G; Njuguna N; Tian X; Soto S; Hughes T; Vire B; Keyvanfar K; Gibellini F; Valdez J; Boss C; Samsel L; McCoy JP; Wilson WH; Pittaluga S; Wiestner A
Haematologica; 2009 Sep; 94(9):1266-73. PubMed ID: 19734418
[TBL] [Abstract][Full Text] [Related]
33. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Costa LJ; Fanning SR; Stephenson J; Afrin LB; Kistner-Griffin E; Bentz TA; Stuart RK
Leuk Lymphoma; 2015 Mar; 56(3):645-9. PubMed ID: 25130476
[TBL] [Abstract][Full Text] [Related]
34. Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo.
Purroy N; Abrisqueta P; Carabia J; Carpio C; Palacio C; Bosch F; Crespo M
Oncotarget; 2015 Apr; 6(10):7632-43. PubMed ID: 25544766
[TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of cytokines released by bone marrow stromal cells from normal donors and B-cell chronic lymphocytic leukemic patients.
Lagneaux L; Delforge A; Bron D; Bosmans E; Stryckmans P
Leuk Lymphoma; 1995 Mar; 17(1-2):127-33. PubMed ID: 7773149
[TBL] [Abstract][Full Text] [Related]
36. Extracellular vesicles of bone marrow stromal cells rescue chronic lymphocytic leukemia B cells from apoptosis, enhance their migration and induce gene expression modifications.
Crompot E; Van Damme M; Pieters K; Vermeersch M; Perez-Morga D; Mineur P; Maerevoet M; Meuleman N; Bron D; Lagneaux L; Stamatopoulos B
Haematologica; 2017 Sep; 102(9):1594-1604. PubMed ID: 28596280
[TBL] [Abstract][Full Text] [Related]
37. A network meta-analysis of maintenance therapy in chronic lymphocytic leukemia.
Lee CH; Chen PH; Lin C; Wang CY; Ho CL
PLoS One; 2020; 15(1):e0226879. PubMed ID: 31995577
[TBL] [Abstract][Full Text] [Related]
38. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.
Zucchetto A; Benedetti D; Tripodo C; Bomben R; Dal Bo M; Marconi D; Bossi F; Lorenzon D; Degan M; Rossi FM; Rossi D; Bulian P; Franco V; Del Poeta G; Deaglio S; Gaidano G; Tedesco F; Malavasi F; Gattei V
Cancer Res; 2009 May; 69(9):4001-9. PubMed ID: 19383907
[TBL] [Abstract][Full Text] [Related]
39. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
40. Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia.
Dal Bo M; Tissino E; Benedetti D; Caldana C; Bomben R; Poeta GD; Gaidano G; Rossi FM; Bulian P; Zucchetto A; Gattei V
Curr Cancer Drug Targets; 2016; 16(8):659-668. PubMed ID: 27514846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
